Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.

NCT00856336 is registered in ClinicalTrials.gov with Antisoma Research as lead sponsor.

NCT NCT00856336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00856336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.
Lead sponsor
Antisoma Research
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2003
Completion date
January 31, 2004
Enrollment
15 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

refractory tumors